Predictive biomarkers of dasatinib treatment in colon cancer patients
Posted in the Colon Cancer Forum
#1 Jul 10, 2011
This recent US patent application from Bristol-Myers Squibb describes the identification of PTK-7, PLK-2 and PLK-3 as markers for determining the responsiveness of cancer to dasatinib (based on cell based assay). Details: http://www.sciclips.com/sciclips/biomarker-ne...
Add your comments below
|Why Are African-Americans at Greater Risk for C... (Jul '17)||Jul '17||SBTAmazing||1|
|My Experience With Colon Cancer (Mar '17)||Mar '17||RustyDodge||2|
|Editorial: Colon Cancer Awareness Should Start ... (Mar '17)||Mar '17||truth is illusion||1|
|Cancer patient donates years' worth of pizza to... (Dec '16)||Dec '16||Knock off purse s...||7|
|Loss of ARID1A protein drives onset and progres... (Dec '16)||Dec '16||Stephany McDowell||1|
|Former employee sues county (Dec '16)||Dec '16||FaTTY||1|
|The 10 commandments of cancer prevention (May '09)||Dec '16||Trying to be hopeful||36|
Find what you want!
Search Colon Cancer Forum Now
Copyright © 2018 Topix LLC